

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/B657623ACF66EN.html>

Date: March 2022

Pages: 63

Price: US\$ 3,250.00 (Single User License)

ID: B657623ACF66EN

Abstracts

This report contains market size and forecasts of B-Cell Maturation Antigen (BCMA) Targeted Therapies in Global, including the following market information:

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Bispecific Antibodies Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of B-Cell Maturation Antigen (BCMA) Targeted Therapies include Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, firstVentury Equity, Five Prime Therapeutics, Credit Suisse Securities, Dana-Farber Cancer Institute and Deerfield Partners, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the B-Cell Maturation Antigen (BCMA) Targeted Therapies companies, and industry experts on this industry, involving

the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segment Percentages, by Type, 2021 (%)

Bispecific Antibodies

Antibody Drug Conjugates

Chimeric Antigen Receptor T-Cells

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segment Percentages, by Application, 2021 (%)

Liver Cancer

Respiratory Cancer

Brain Cancer

Others

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies B-Cell Maturation Antigen (BCMA) Targeted Therapies revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies B-Cell Maturation Antigen (BCMA) Targeted Therapies revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Transposagen Biopharmaceuticals

Sutro Biopharma

Malin Corporation

Eureka Therapeutics

firstVentury Equity

Five Prime Therapeutics

Credit Suisse Securities

Dana-Farber Cancer Institute

Deerfield Partners

Onyx Pharmaceuticals

Juno Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL B-CELL MATURATION ANTIGEN (BCMA) TARGETED THERAPIES OVERALL MARKET SIZE

- 2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size: 2021 VS 2028
- 2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players in Global Market
- 3.2 Top Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies Ranked by Revenue
- 3.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Companies
- 3.4 Top 3 and Top 5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Type

3.6 Tier 1, Tier 2 and Tier 3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players in Global Market

3.6.1 List of Global Tier 1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies

3.6.2 List of Global Tier 2 and Tier 3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Markets, 2021 & 2028

4.1.2 Bispecific Antibodies

4.1.3 Antibody Drug Conjugates

4.1.4 Chimeric Antigen Receptor T-Cells

4.2 By Type - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue & Forecasts

4.2.1 By Type - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, 2017-2022

4.2.2 By Type - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, 2023-2028

4.2.3 By Type - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2021 & 2028

5.1.2 Liver Cancer

5.1.3 Respiratory Cancer

5.1.4 Brain Cancer

5.1.5 Others

5.2 By Application - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue & Forecasts

5.2.1 By Application - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, 2017-2022

5.2.2 By Application - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue, 2023-2028

5.2.3 By Application - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
Size, 2021 & 2028

6.2 By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue
& Forecasts

6.2.1 By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, 2017-2022

6.2.2 By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, 2023-2028

6.2.3 By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America B-Cell Maturation Antigen (BCMA) Targeted
Therapies Revenue, 2017-2028

6.3.2 US B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.3.3 Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.3.4 Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.4 Europe

6.4.1 By Country - Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, 2017-2028

6.4.2 Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.4.3 France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.4.4 U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.4.5 Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.4.6 Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size,
2017-2028

6.4.7 Nordic Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

Size, 2017-2028

6.4.8 Benelux B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, 2017-2028

6.5.2 China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.5.3 Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.5.4 South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.5.5 Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.5.6 India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, 2017-2028

6.6.2 Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.6.3 Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, 2017-2028

6.7.2 Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.7.3 Israel B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.7.4 Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

6.7.5 UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Transposagen Biopharmaceuticals

7.1.1 Transposagen Biopharmaceuticals Corporate Summary

- 7.1.2 Transposagen Biopharmaceuticals Business Overview
- 7.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
- 7.1.4 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
- 7.1.5 Transposagen Biopharmaceuticals Key News
- 7.2 Sutro Biopharma
 - 7.2.1 Sutro Biopharma Corporate Summary
 - 7.2.2 Sutro Biopharma Business Overview
 - 7.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.2.4 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.2.5 Sutro Biopharma Key News
- 7.3 Malin Corporation
 - 7.3.1 Malin Corporation Corporate Summary
 - 7.3.2 Malin Corporation Business Overview
 - 7.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.3.4 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.3.5 Malin Corporation Key News
- 7.4 Eureka Therapeutics
 - 7.4.1 Eureka Therapeutics Corporate Summary
 - 7.4.2 Eureka Therapeutics Business Overview
 - 7.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.4.4 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.4.5 Eureka Therapeutics Key News
- 7.5 firstVentury Equity
 - 7.5.1 firstVentury Equity Corporate Summary
 - 7.5.2 firstVentury Equity Business Overview
 - 7.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.5.4 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.5.5 firstVentury Equity Key News
- 7.6 Five Prime Therapeutics

- 7.6.1 Five Prime Therapeutics Corporate Summary
- 7.6.2 Five Prime Therapeutics Business Overview
- 7.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
- 7.6.4 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
- 7.6.5 Five Prime Therapeutics Key News
- 7.7 Credit Suisse Securities
 - 7.7.1 Credit Suisse Securities Corporate Summary
 - 7.7.2 Credit Suisse Securities Business Overview
 - 7.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.7.4 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.7.5 Credit Suisse Securities Key News
- 7.8 Dana-Farber Cancer Institute
 - 7.8.1 Dana-Farber Cancer Institute Corporate Summary
 - 7.8.2 Dana-Farber Cancer Institute Business Overview
 - 7.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.8.4 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.8.5 Dana-Farber Cancer Institute Key News
- 7.9 Deerfield Partners
 - 7.9.1 Deerfield Partners Corporate Summary
 - 7.9.2 Deerfield Partners Business Overview
 - 7.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.9.4 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.9.5 Deerfield Partners Key News
- 7.10 Onyx Pharmaceuticals
 - 7.10.1 Onyx Pharmaceuticals Corporate Summary
 - 7.10.2 Onyx Pharmaceuticals Business Overview
 - 7.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Major Product Offerings
 - 7.10.4 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global Market (2017-2022)
 - 7.10.5 Onyx Pharmaceuticals Key News

7.11 Juno Therapeutics

7.11.1 Juno Therapeutics Corporate Summary

7.11.2 Juno Therapeutics Business Overview

7.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies

Major Product Offerings

7.11.4 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue in Global Market (2017-2022)

7.11.5 Juno Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Opportunities & Trends in Global Market

Table 2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers in Global Market

Table 3. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints in Global Market

Table 4. Key Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies in Global Market

Table 5. Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players in Global Market, Ranking by Revenue (2021)

Table 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Companies, 2017-2022

Table 8. Global Companies B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Type

Table 9. List of Global Tier 1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2023-2028

Table 30. Transposagen Biopharmaceuticals Corporate Summary

Table 31. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 32. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 33. Sutro Biopharma Corporate Summary

Table 34. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 35. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 36. Malin Corporation Corporate Summary

Table 37. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 38. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 39. Eureka Therapeutics Corporate Summary

Table 40. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 41. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 42. firstVentury Equity Corporate Summary

Table 43. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 44. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 45. Five Prime Therapeutics Corporate Summary

Table 46. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 47. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 48. Credit Suisse Securities Corporate Summary

Table 49. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 50. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 51. Dana-Farber Cancer Institute Corporate Summary

Table 52. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 53. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 54. Deerfield Partners Corporate Summary

Table 55. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 56. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 57. Onyx Pharmaceuticals Corporate Summary

Table 58. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 59. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

Table 60. Juno Therapeutics Corporate Summary

Table 61. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offerings

Table 62. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Segment by Type in 2021

Figure 2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Segment by Application in 2021

Figure 3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2021

Figure 8. By Type - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 9. By Application - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 10. By Region - Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 11. By Country - North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 12. US B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 16. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 17. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 24. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 28. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 30. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share, 2017-2028

Figure 33. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, (US\$, Mn), 2017-2028

Figure 37. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted

Therapies Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted

Therapies Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted

Therapies Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted

Therapies Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/B657623ACF66EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B657623ACF66EN.html>